CN103282378B - 多肽及其在治疗和限制呼吸道合胞病毒感染中的用途 - Google Patents

多肽及其在治疗和限制呼吸道合胞病毒感染中的用途 Download PDF

Info

Publication number
CN103282378B
CN103282378B CN201180058569.8A CN201180058569A CN103282378B CN 103282378 B CN103282378 B CN 103282378B CN 201180058569 A CN201180058569 A CN 201180058569A CN 103282378 B CN103282378 B CN 103282378B
Authority
CN
China
Prior art keywords
polypeptide
rsv
vlp
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180058569.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103282378A (zh
Inventor
威廉·R·席夫
布鲁诺·E·科雷亚
戴维·贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington Center for Commercialization
Original Assignee
University of Washington Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington Center for Commercialization filed Critical University of Washington Center for Commercialization
Publication of CN103282378A publication Critical patent/CN103282378A/zh
Application granted granted Critical
Publication of CN103282378B publication Critical patent/CN103282378B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180058569.8A 2010-10-06 2011-10-06 多肽及其在治疗和限制呼吸道合胞病毒感染中的用途 Expired - Fee Related CN103282378B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39059110P 2010-10-06 2010-10-06
US61/390,591 2010-10-06
PCT/US2011/055113 WO2012048115A2 (en) 2010-10-06 2011-10-06 Polypeptides and their use in treating and limiting respiratory syncytial virus infection

Publications (2)

Publication Number Publication Date
CN103282378A CN103282378A (zh) 2013-09-04
CN103282378B true CN103282378B (zh) 2015-03-11

Family

ID=44993163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180058569.8A Expired - Fee Related CN103282378B (zh) 2010-10-06 2011-10-06 多肽及其在治疗和限制呼吸道合胞病毒感染中的用途

Country Status (7)

Country Link
US (1) US9718862B2 (enExample)
EP (1) EP2625194B1 (enExample)
JP (1) JP6023061B2 (enExample)
CN (1) CN103282378B (enExample)
AU (1) AU2011311946B8 (enExample)
CA (1) CA2813752A1 (enExample)
WO (1) WO2012048115A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2813752A1 (en) 2010-10-06 2012-04-12 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
WO2013152274A1 (en) * 2012-04-05 2013-10-10 University Of Washington Through Its Center For Commercialization Epitope- scaffold immunogens against respiratory syncytial virusm (rsv)
WO2017081082A2 (en) * 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
MX2019014719A (es) 2017-06-14 2020-08-03 Virometix Ag Peptidos ciclicos para proteccion contra el virus sincitial respiratorio.
CN113260377B (zh) 2018-12-20 2025-08-22 维罗米蒂克斯股份公司 脂肽构建块和合成病毒样颗粒
CN110853704B (zh) * 2019-11-11 2020-11-06 腾讯科技（深圳）有限公司 蛋白质数据获取方法、装置、计算机设备及存储介质

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668335A (zh) * 2002-05-17 2005-09-14 免疫医疗公司 通过包含载体肽和活性剂的双特异性抗体和半抗原构建体的方式进行药物前靶向定位
WO2009079796A1 (en) * 2007-12-24 2009-07-02 Id Biomedical Corporation Of Quebec Recombinant rsv antigens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
ES2317711T3 (es) 1998-11-30 2009-04-16 Cytos Biotechnology Ag Presentacion molecular de alergenos, metodos de preparacion y uso.
US6955717B2 (en) 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
CN1659187A (zh) 2002-05-10 2005-08-24 新世纪药品有限公司 融合铁蛋白在疫苗和其他方面的应用
EP1793850A4 (en) 2004-09-21 2010-06-30 Medimmune Inc ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
WO2008025015A2 (en) 2006-08-25 2008-02-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epitope-protein scaffolds and their use
WO2009100376A2 (en) 2008-02-07 2009-08-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antigenic cloaking and its use
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
CA2813752A1 (en) 2010-10-06 2012-04-12 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
WO2013152274A1 (en) 2012-04-05 2013-10-10 University Of Washington Through Its Center For Commercialization Epitope- scaffold immunogens against respiratory syncytial virusm (rsv)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668335A (zh) * 2002-05-17 2005-09-14 免疫医疗公司 通过包含载体肽和活性剂的双特异性抗体和半抗原构建体的方式进行药物前靶向定位
WO2009079796A1 (en) * 2007-12-24 2009-07-02 Id Biomedical Corporation Of Quebec Recombinant rsv antigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Development of Motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract;Wu et al.;《Journal of molecular biology》;Acadamic press, United Kingdom;20070406;第368卷(第3期);第652-665页 *
呼吸道合胞病毒的蛋白特征及抗原变异;芦起;《国外医学病毒学分册》;20050630;第12卷(第3期);第76-80页 *
抗呼吸道合胞病毒(RSV)单克隆抗体的制备及其对RSV制备及其对RSV病毒株抗原性的分析;田慕贞等;《中国病毒学》;19920701;第7卷(第2期);第181-185页 *

Also Published As

Publication number Publication date
EP2625194A2 (en) 2013-08-14
CN103282378A (zh) 2013-09-04
AU2011311946B8 (en) 2014-10-09
US20130280262A1 (en) 2013-10-24
JP6023061B2 (ja) 2016-11-09
AU2011311946A1 (en) 2013-05-02
JP2014502143A (ja) 2014-01-30
CA2813752A1 (en) 2012-04-12
AU2011311946B2 (en) 2014-10-02
EP2625194B1 (en) 2015-08-12
US9718862B2 (en) 2017-08-01
WO2012048115A2 (en) 2012-04-12
WO2012048115A3 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
TWI663175B (zh) 穩定化可溶性融合前ｒｓｖ ｆ多肽
CN103282378B (zh) 多肽及其在治疗和限制呼吸道合胞病毒感染中的用途
TWI810589B (zh) 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
WO2023186170A1 (zh) 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用
EP2834263B9 (en) Epitope-scaffold immunogens against respiratory syncytial virusm (rsv)
WO2022081870A1 (en) Stabilized norovirus virus-like particles as vaccine immunogens
EP3518968B1 (en) Hiv-1 env fusion peptide immunogens and their use
CN110551187B (zh) 化学合成的h7n9禽流感病毒na蛋白胞外区抗原片段及制备方法和应用
JP2025172875A (ja) パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
US20220289796A1 (en) Methods and compositions for stabilized recombinant flavivirus e protein dimers
US20190117756A1 (en) Immunogenic Compositions and Vaccines Derived From Bacterial Surface Receptor Proteins
US20240262869A1 (en) POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOF
US20150044248A1 (en) Polypeptides and their use in treating metapneumovirus (mpv) infection
US20250188131A1 (en) Viral proteins and nanostructures and uses thereof
US20250090651A1 (en) Respiratory syncytial virus f proteins and nanostructures and uses thereof
WO2018175518A1 (en) Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
WO2023138648A1 (zh) SARS-CoV-2刺突蛋白变体、其药物组合物及用途
CN116745408A (zh) 稳定的冠状病毒刺突蛋白融合蛋白
TW202500574A (zh) 冠狀病毒刺突醣蛋白受體結合域及其用途
WO2022179318A1 (zh) 基于s蛋白r815位点的冠状病毒干预的方法和产品

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Schief William R

Inventor after: Correla Bruno E

Inventor before: Schief William R

Inventor before: Correla Bruno E

Inventor before: Baker David

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: WILLIAM R. SCHIEF BRUNO E. CORRELA BAKER DAVID TO: WILLIAM R. SCHIEF BRUNO E. CORRELA

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150311

Termination date: 20191006